Cited 10 times in
Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강훈철 | - |
dc.contributor.author | 김흥동 | - |
dc.contributor.author | 이준수 | - |
dc.date.accessioned | 2019-03-15T02:24:24Z | - |
dc.date.available | 2019-03-15T02:24:24Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0387-7604 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/167442 | - |
dc.description.abstract | PURPOSE: The treatment options for Lennox-Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents <20 years of age with LGS. This subgroup analysis aimed to evaluate the efficacy and safety of rufinamide tablets in LGS pediatric patients aged 1-4 years. METHODS: This was a retrospective, observational study in LGS patients aged 1-4 years who received 12 weeks of treatment with rufinamide orally as an adjuvant treatment between April and June 2010. The proportion of responders (patients with a ≥50% reduction in seizure frequency after rufinamide treatment) was evaluated according to the type of seizure. The proportion of patients who were seizure-free was also evaluated. Adverse events (AEs) were evaluated after 12 weeks of treatment. RESULTS: Among the 15 patients evaluated, one discontinued treatment because of worsening seizures 4 weeks after administration of rufinamide. Seven (46.67%) patients were responders and four patients were seizure-free. There were four responders with convulsive seizures, one each for myoclonic seizures and drop attacks, and spasms. The responder rate was increased to 69.23% by long-term treatment of rufinamide. AEs were experienced by three patients. One patient each experienced somnolence, fatigue, and rash. CONCLUSION: Rufinamide tablets were efficacious and well tolerated in LGS patients aged 1-4 years, at doses up to 1000 mg per day, when given as add-on therapy to other antiepileptic drugs. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | BRAIN & DEVELOPMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adjuvants, Pharmaceutic | - |
dc.subject.MESH | Anticonvulsants/administration & dosage | - |
dc.subject.MESH | Anticonvulsants/adverse effects | - |
dc.subject.MESH | Anticonvulsants/pharmacology* | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Lennox Gastaut Syndrome/drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Outcome Assessment (Health Care)* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Triazoles/administration & dosage | - |
dc.subject.MESH | Triazoles/adverse effects | - |
dc.subject.MESH | Triazoles/pharmacology* | - |
dc.title | Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아청소년과학교실) | - |
dc.contributor.googleauthor | Shin Hye Kim | - |
dc.contributor.googleauthor | Hoon-Chul Kang | - |
dc.contributor.googleauthor | Joon Soo Lee | - |
dc.contributor.googleauthor | Heung Dong Kim | - |
dc.identifier.doi | 10.1016/j.braindev.2018.07.020 | - |
dc.contributor.localId | A00102 | - |
dc.contributor.localId | A01208 | - |
dc.contributor.localId | A03177 | - |
dc.relation.journalcode | J00386 | - |
dc.identifier.eissn | 1872-7131 | - |
dc.identifier.pmid | 30166208 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S038776041830384X | - |
dc.subject.keyword | Efficacy | - |
dc.subject.keyword | Lennox–Gastaut syndrome | - |
dc.subject.keyword | Pediatric | - |
dc.subject.keyword | Rufinamide | - |
dc.subject.keyword | Safety | - |
dc.contributor.alternativeName | Kang, Hoon Chul | - |
dc.contributor.affiliatedAuthor | 강훈철 | - |
dc.contributor.affiliatedAuthor | 김흥동 | - |
dc.contributor.affiliatedAuthor | 이준수 | - |
dc.citation.volume | 40 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 897 | - |
dc.citation.endPage | 903 | - |
dc.identifier.bibliographicCitation | BRAIN & DEVELOPMENT, Vol.40(10) : 897-903, 2018 | - |
dc.identifier.rimsid | 48789 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.